SLAMF7 and Miyoshi myopathy: The function and structural elucidation of Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7) helped pave the way for a new monoclonal antibody target and was approved by the FDA in 2015 for use with Lenalidomide and Dexamethasone in those who have had previous treatment for MM.